Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 12Unknown 5Terminated 3Recruiting 3Withdrawn 1Suspended 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 1

Conditions

Leukemia, Myeloid, Acute 4Prostatic Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Advanced Solid Tumor 3Pancreatic Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Hypoxia 2Advanced Solid Tumors 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pelvic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Injections × Clear all
NCT02751528 2025-01-13

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

NantBioScience, Inc.

Phase 1 Terminated
3 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Breast Neoplasms, Male

NCT02508441 2018-10-18

Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

Andes Biotechnologies

Phase 1 Terminated
22 enrolled
Tumor-Agnostic

Neoplasms

NCT00088023 2014-03-31

Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness

Spectrum Pharmaceuticals, Inc

Phase 1 Terminated
40 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡